1. Home
  2. CRSP vs CPK Comparison

CRSP vs CPK Comparison

Compare CRSP & CPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • CPK
  • Stock Information
  • Founded
  • CRSP 2013
  • CPK 1990
  • Country
  • CRSP Switzerland
  • CPK United States
  • Employees
  • CRSP 393
  • CPK N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • CPK Oil & Gas Production
  • Sector
  • CRSP Health Care
  • CPK Utilities
  • Exchange
  • CRSP Nasdaq
  • CPK Nasdaq
  • Market Cap
  • CRSP 3.3B
  • CPK 3.0B
  • IPO Year
  • CRSP 2016
  • CPK N/A
  • Fundamental
  • Price
  • CRSP $35.62
  • CPK $126.82
  • Analyst Decision
  • CRSP Buy
  • CPK Hold
  • Analyst Count
  • CRSP 17
  • CPK 3
  • Target Price
  • CRSP $74.53
  • CPK $122.67
  • AVG Volume (30 Days)
  • CRSP 2.0M
  • CPK 132.1K
  • Earning Date
  • CRSP 05-06-2025
  • CPK 05-07-2025
  • Dividend Yield
  • CRSP N/A
  • CPK 2.16%
  • EPS Growth
  • CRSP N/A
  • CPK 9.39
  • EPS
  • CRSP N/A
  • CPK 5.43
  • Revenue
  • CRSP $37,675,000.00
  • CPK $840,200,000.00
  • Revenue This Year
  • CRSP $51.35
  • CPK $10.63
  • Revenue Next Year
  • CRSP $282.16
  • CPK $4.42
  • P/E Ratio
  • CRSP N/A
  • CPK $23.41
  • Revenue Growth
  • CRSP N/A
  • CPK 20.34
  • 52 Week Low
  • CRSP $30.04
  • CPK $102.64
  • 52 Week High
  • CRSP $67.88
  • CPK $136.73
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 44.74
  • CPK 39.42
  • Support Level
  • CRSP $33.03
  • CPK $131.58
  • Resistance Level
  • CRSP $39.38
  • CPK $136.28
  • Average True Range (ATR)
  • CRSP 1.81
  • CPK 3.01
  • MACD
  • CRSP -0.19
  • CPK -0.67
  • Stochastic Oscillator
  • CRSP 33.64
  • CPK 5.57

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About CPK Chesapeake Utilities Corporation

Chesapeake Utilities Corp is a diversified energy delivery company that is engaged in natural gas transmission and distribution, electricity generation and distribution, propane gas distribution, mobile compressed natural gas utility services and solutions and other businesses. The company operates in two reportable segments, Regulated Energy and Unregulated Energy. The company's natural gas and electric distribution operations in Delaware, Maryland and Florida are subject to regulation by PSC. Eastern Shore, its natural gas transmission is subject to regulation by the FERC and Peninsula Pipeline and Aspire Energy Express, its intrastate pipeline subsidiaries, are subject to regulation by the Florida PSC and Public Utilities Commission of Ohio, respectively.

Share on Social Networks: